Tina W.’s Post

AI-powered cancer treatments just took another step forward. Our portfolio company, Unnatural Products Inc. (UNP), has launched a research partnership with global pharmaceutical company Merck to design and develop new oncology therapeutics. UNP’s expert team combines machine learning with parallel chemistry to identify macrocyclic treatments, a powerful structure that targets multiple cells with enhanced precision.  With a focus on challenging cancer targets, the new partnership will apply cutting-edge technology to address one of society’s most difficult-to-treat diseases. It’s a promising development in the oncology field with life-saving potential.   Find the full announcement details here: https://lnkd.in/gHf-CSU9  #AI #Oncology #VentureCapital #Longevity #cancertreatment

#News: Apparently, C4 Therapeutics, Inc. ' #proteindegradation tech brings all the #Mercks to the yard. The Massachusetts #biotech has signed on MSD in a $740 million biobucks partnership to find two #degraders for #cancer. #MerckKGaA is offering $16 million upfront and $740 million in #biobucks for the two degraders aimed at proteins that drive cancer growth. Merck will pay for C4’s discovery work and be responsible for future clinical development, according to Monday's announcement. C4 also stands to make mid single- to low double-digit royalties should any of the targets turn into marketed drugs. Paul Lyne , head of Merck KGaA’s oncology research unit, said the deal adds more depth to the company’s protein degradation investments. Read more from Fierce Biotech 👇🏽 https://lnkd.in/e-f7TuHZ

Five months after $105M from a pre-IPO crossover round, CG Oncology is going public. #biotech #biotechnology #biotechnologie #oncology #clinicalresearch #biopharma #biopharmaceutical #biopharmaceuticals #researchanddevelopment

📣 Adcendo has been featured in Clarivate for Life Sciences & Healthcare's "Companies to Watch: Antibody Drug Conjugates" report! 📰 The report highlights this exciting field of therapeutics and shines a spotlight on companies making an impact in the #lifesciences and #healthcare space. Adcendo is highlighted as one of seven companies that are advancing antibody-drug conjugates (#ADCs) to deliver highly targeted cancer treatments with an improved therapeutic window. Find out more about what makes us stand out, our R&D activities to date, and much more in the report here: https://lnkd.in/eWhSzAWz #biotech #oncology #lifesciences

Today Clarivate announced its annual Companies to Watch report, highlighting seven innovative companies revolutionizing drug discovery and development. These companies are advancing antibody-drug conjugates (ADCs) to deliver highly targeted cancer treatments with minimal side effects. Based on data, insights and analysis of drug benefits, financing and R&D activity, the report explores why these companies are significant innovators.    You can download the report, here: Companies to Watch: Antibody Drug Conjugates - Clarivate

"Over 20 years since the first ADC was approved, the approach — using antibodies’ specificity for targeted delivery of potent cytotoxic drugs — is coming of age." Here's a solid overview of ADCs in cancer precision medicine, covering current R&D and past drug launches in the field. This article does a great job explaining ADC 'linker chemistry' evolving technology, along with progress in expanding cytotoxic/chemotherapy payload delivery. #oncology #oncologyresearch #precisionmedicine #precisiononcology #pharma #biopharma

𝐏𝐡𝐞𝐨𝐧 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐒𝐞𝐜𝐮𝐫𝐞𝐬 $𝟏𝟐𝟎𝐌 𝐒𝐞𝐫𝐢𝐞𝐬 𝐁 𝐭𝐨 𝐀𝐝𝐯𝐚𝐧𝐜𝐞 𝐀𝐃𝐂 𝐏𝐢𝐩𝐞𝐥𝐢𝐧𝐞 Pheon Therapeutics Pheon Therapeutics, a leader in developing next-generation Antibody-Drug Conjugates (ADCs) for hard-to-treat cancers, has completed a $120M Series B financing. Led by TCGX, with participation from BVF Partners, Lightspeed, Perceptive Advisors, and existing investors Atlas Venture, Brandon Capital, Forbion, and Research Corporation Technologies, this funding will advance Pheon’s ADC pipeline. The financing will support clinical proof of concept for Pheon’s first three ADC assets targeting a novel antigen overexpressed in solid tumors. The lead program, featuring a DAR8 Topoisomerase-1 inhibitor linker-payload, has shown an unprecedented preclinical therapeutic index. Phase 1 clinical trials are set to begin in 2024. Cyrus Mozayeni MD Cyrus Mozayeni, CEO of Pheon, said: “This raise is critical as we transition into a clinical-stage company. We are excited about our promising candidates and their potential therapeutic benefits.” Cariad Chester Cariad Chester, Managing Partner of TCGX, added: “The success of optimized ADC constructs highlights their promise in treating solid tumors. Pheon’s pipeline is impressive, and I look forward to supporting their growth.” Chester will join Pheon’s board as part of the financing. #Biotech #CancerResearch #ADCTherapeutics #HealthcareInnovation #ClinicalTrials #Pharma #Oncology #Investment #MedicalResearch #NextGenTherapies #CancerTreatment #VentureCapital #SeriesBFunding #AntibodyDrugConjugates #SolidTumors

Clarivate released the 2024 Companies to Watch report, highlighting seven innovative companies advancing antibody drug conjugates (ADCs) to deliver highly targeted cancer treatments with minimal side effects. The companies - Adcendo, Araris Biotech AG, GO Therapeutics, Heidelberg Pharma AG, Pheon Therapeutics, Tallac Therapeutics, Tubulis GmbH – are transforming drug discovery and development, revolutionizing cancer treatment, and capturing big pharma interest. The report, based on data from BioWorld News and an analysis of drug benefits, financing, and R&D activity, explains why these companies are significant innovators. "Data reveals a clear trend: Big Pharma is swiftly integrating ADCs into their portfolios through partnerships and acquisitions. ADCs are rapidly maturing in the clinical space, expanding beyond oncology into diverse therapeutic areas” quotes Mike Ward, Global Head of Life Sciences and Healthcare Thought Leadership at Clarivate. Read more: https://lnkd.in/ezuGNPBk #oncology #cancertreatment #drugdiscovery #pharma

C4 Therapeutics, Inc. Strikes $740 Million Partnership ($16 Million upfront) with Merck KGaA, Darmstadt, Germany for Cancer Protein Degradation targeting cancer. C4 Therapeutics will utilize its proprietary TORPEDO® platform to discover two degraders targeting undisclosed oncogenic proteins, which could be incorporated in C4T's degrader-antibody conjugate (DAC). Merck KGaA will be responsible for clinical development and commercialization. After ADC, AOC and Antibody Radionuclide Conjugates, DAC is another emerging modality of antibody based biologics. Novel modalities of biologics are indeed the major topics of our society's 2024 Annual Conference which will take place in Cambridge, MA, USA, on Saturday, May 11, 2024. You are welcome to register the conference RIGHT NOW via the following link. https://lnkd.in/ecmFPA4v #degraderantibodyconjugate #antibodydiscovery #antibodydrugconjugates #oncology #annualmeeting #annualconference

Delighted to have the attended the first official General Assembly meeting of the PSCC Connect network, part of the Paris Saclay Cancer Cluster, this afternoon. I enjoyed hearing the PSCC team explain the working structure, budget and future plans of the network, meeting fellow members and hearing elevator pitches from 20 Oncology start-ups, encompassing ADCs (MIO / McSAF), Biologics (ABCELY), Small-Molecule Drugs (Promontory Therapeutics), Cell Therapies (PERSEA), Anti-Cancer Vaccines (Brenus Pharma, ErVimmune), Drug Repurposing (PEGASCY) and various other domains (HEPHAISTOS-Pharma and so many others...). Photo: various attendees. Inset: Gregory Qushair (Alésia Consulting) with Wahid Awad, Ph.D. MBA (Rosetta Omics). ABCELYARDAN PHARMA Serendip innovations Apmonia Therapeutics Exosome Analytics GIMLI Jalon Therapeutics MSInsight PepKon #oncology #biotechnology #pharmaceuticals #diagnostics #cancer #paris #drugdiscovery #celltherapy #immunotherapy #omics